Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary central nervous system lymphoma.

Hendrik Pels1, Uwe Schlegel

  • 1Department of Neurology, Ruhr-University Bochum, Knappschaftskrankenhaus, In der Schornau 23-25, D-44892 Bochum, Germany.

Current Treatment Options in Neurology
|September 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Neuro-oncology: challenges and perspectives].

Der Nervenarzt·2024
Same author

Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.

Journal of neuro-oncology·2023
Same author

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.

Journal of neuro-oncology·2023
Same author

Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up.

Journal of neuro-oncology·2023
Same author

Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis.

Neurological research and practice·2023
Same author

Pre- and postoperative self-reported and objectively assessed neurocognitive functioning in lower grade glioma patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2022

Primary central nervous system lymphoma (PCNSL) treatment lacks Class I evidence. High-dose methotrexate-based chemotherapy offers long-term survival and potential cure in younger patients, but toxicity is a concern in older adults.

Area of Science:

  • Neuro-oncology
  • Hematology
  • Clinical Therapeutics

Background:

  • Primary central nervous system lymphoma (PCNSL) lacks definitive evidence-based therapeutic guidelines.
  • Current treatment strategies are limited, with surgery primarily for diagnosis and radiotherapy alone offering poor long-term outcomes.
  • The therapeutic aim for younger patients (<60 years) is cure, while established curative regimens with acceptable toxicity are lacking for older patients (>60 years).

Purpose of the Study:

  • To review the current therapeutic landscape for primary central nervous system lymphoma (PCNSL).
  • To highlight the efficacy and limitations of various treatment modalities, including chemotherapy and radiotherapy.
  • To discuss treatment considerations based on patient age and potential toxicities.

Main Methods:

Related Experiment Videos

  • Review of existing literature and clinical evidence for primary central nervous system lymphoma (PCNSL) treatment.
  • Analysis of treatment outcomes, focusing on survival, cure rates, and toxicity profiles.
  • Consideration of specific chemotherapeutic agents, particularly high-dose methotrexate.

Main Results:

  • High-dose methotrexate, especially in combination with other agents, is the most effective drug for PCNSL, yielding long-term survival and potential cure in younger patients.
  • Radiotherapy alone provides limited survival benefits (median 1.5 years), with cure being exceptional.
  • Combination therapy with radiotherapy and methotrexate-based chemotherapy leads to significant long-term neurotoxicity, particularly in older patients.

Conclusions:

  • High-dose methotrexate-based polychemotherapy is crucial for achieving long-term survival and cure in eligible primary central nervous system lymphoma (PCNSL) patients.
  • Clinical trials are essential for advancing therapeutic options in PCNSL.
  • Age is a critical factor in treatment decisions due to the risk of severe neurotoxicity, especially in elderly patients.